Genmab downgraded after HuMax-CD20 success brings "unneccesary" R&D cost rise
This article was originally published in Scrip
Executive Summary
Cannacord Adamsanalysts have revised their recommendation for Genmabfrom buy to hold, following the company's recent stock price appreciation attributed to positive HuMax-CD20 (ofatumumab) Phase III chronic lymphocytic leukaemia (CLL) results. The analysts said that while they recognise Genmab's recent clinical success and other positive news about the company this year, they still had concerns.